Bayer AG
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast age… Read more
Bayer AG (BAYZF) - Total Liabilities
Latest total liabilities as of December 2024: $78.81 Billion USD
Based on the latest financial reports, Bayer AG (BAYZF) has total liabilities worth $78.81 Billion USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bayer AG - Total Liabilities Trend (2004–2024)
This chart illustrates how Bayer AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bayer AG Competitors by Total Liabilities
The table below lists competitors of Bayer AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AIB Group plc
PINK:AIBGY
|
USA | $129.99 Billion |
|
Constellation Brands Inc Class A
NYSE:STZ
|
USA | $13.68 Billion |
|
Telefonaktiebolaget LM Ericsson Class B
PINK:ERIXF
|
USA | $168.54 Billion |
|
Oriental Land Co. Ltd
PINK:OLCLF
|
USA | $511.72 Billion |
|
Heidelberg Materials AG
XETRA:HEI
|
Germany | €16.49 Billion |
|
Ares Management LP
NYSE:ARES
|
USA | $-8.63 Billion |
|
Accton Technology Corp
TW:2345
|
Taiwan | NT$88.09 Billion |
|
Williams-Sonoma Inc
NYSE:WSM
|
USA | $3.24 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Bayer AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bayer AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bayer AG (2004–2024)
The table below shows the annual total liabilities of Bayer AG from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $78.81 Billion | -5.26% |
| 2023-12-31 | $83.18 Billion | -3.22% |
| 2022-12-31 | $85.95 Billion | -1.29% |
| 2021-12-31 | $87.07 Billion | +0.84% |
| 2020-12-31 | $86.35 Billion | +9.66% |
| 2019-12-31 | $78.74 Billion | -1.74% |
| 2018-12-31 | $80.14 Billion | +109.64% |
| 2017-12-31 | $38.23 Billion | -24.07% |
| 2016-12-31 | $50.34 Billion | +3.86% |
| 2015-12-31 | $48.47 Billion | -19.89% |
| 2014-12-31 | $60.51 Billion | +98.30% |
| 2013-12-31 | $30.51 Billion | -46.50% |
| 2006-12-31 | $57.03 Billion | +88.36% |
| 2005-12-31 | $30.28 Billion | -9.15% |
| 2004-12-31 | $33.33 Billion | -- |